Caizhi Yaocheng Biotechnology

Caizhi Yaocheng Biotechnology is a Hangzhou-based biopharmaceutical company specializing in the discovery and development of innovative macrocyclic peptide therapeutics. The company leverages a proprietary platform that integrates high-throughput DNA-encoded library (DEL) technology with artificial intelligence and advanced chemical synthesis to tackle challenging protein-protein interaction (PPI) targets. Their research focuses primarily on developing next-generation treatments for oncology, immunology, and metabolic disorders. By combining the specificity of biologics with the oral bioavailability potential of small molecules, Caizhi Yaocheng aims to provide novel solutions for previously undruggable targets. The company is backed by prominent venture capital firms and operates out of a dedicated R&D facility in China.